Rowan University Rowan Digital Works

Stratford Campus Research Day

26th Annual Research Day

May 5th, 12:00 AM

Factors Associated with Unplanned Conversion to Open in Nephrectomy for Kidney Cancer

Young Son Rowan University

Benjamin A. Fink Rowan University

Justine Garfinkel Rowan University

Lance Earnshaw Rowan University

Brian Thomas *Rowan University*

See next page for additional authors Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

C Part of the Nephrology Commons, Surgery Commons, Surgical Procedures, Operative Commons, and the Urogenital System Commons

Let us know how access to this document benefits you - share your thoughts on our feedback form.

Son, Young; Fink, Benjamin A.; Garfinkel, Justine; Earnshaw, Lance; Thomas, Brian; Mueller, Thomas; and Sussman, David, "Factors Associated with Unplanned Conversion to Open in Nephrectomy for Kidney Cancer" (2022). *Stratford Campus Research Day*. 65. https://rdw.rowan.edu/stratford_research_day/2022/May5/65

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of Rowan Digital Works.

Author(s)

Young Son, Benjamin A. Fink, Justine Garfinkel, Lance Earnshaw, Brian Thomas, Thomas Mueller, and David Sussman

This poster is available at Rowan Digital Works: https://rdw.rowan.edu/stratford_research_day/2022/May5/65



Factors Associated with Unplanned Conversion to Open in Nephrectomy for Kidney Cancer

Young Son, D.O., Benjamin A.Fink OMS3, Justine Garfinkel OMS3, Lance Earnshaw OMS4, Brain Thomas OMS3, Thomas Mueller, M.D., David Sussman, D.O.

Jefferson New Jersey Urology, 18 E. Laurel Rd., Stratford, NJ 08084

Tables

Background

Minimally invasive surgery (MIS) has been adopted as an approach in kidney surgery. Laparoscopic kidney surgery has been introduced in the 1990s with robotics emerging a decade after.^{1,2} The minimally invasive approach has been technically feasible and has been shown to be noninferior with preserved oncology standards to open surgery.³ The ubiquitous use of MIS for kidney cancer has been standard of practice; however, unplanned conversion to open kidney surgery has been characterized at 4.9% for laparoscopic radical nephrectomy compared to 6.0% in robotic radical nephrectomy.⁴ Another analysis of 54,246 patients undergoing partial nephrectomy for kidney cancer observed an unplanned open conversion rate of 2.87% for cT1 renal masses. Furthermore, the unplanned conversion to open radical or partial nephrectomy after an attempted minimally invasive approach has been an independent predictor of increased risk of 30-day hospital readmission.⁵ Currently, the relative risk factors to predict unplanned conversion to open surgery has not been well characterized. Greater understanding of risk factors for unplanned open conversion has clinical implications to reduce intraoperative and postoperative outcomes. The early recognition of nationwide risk and predictors may aid in identifying patients for planned open kidney surgery. We aim to use the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database to identify predictors and outcomes in a contemporary cohort.

Methods

The 2019 and 2020 NSQIP data was analyzed in a retrospective cohort study of radical cystectomy patients. A total of 14,186 patients were evaluated and 4.862 patients met the inclusion criteria of nephrectomy performed for kidney cancer. The groups were then subcategorized to planned MIS only (endoscopic, laparoscopic, other MIS, and robotic) (n=4756) and unplanned conversion to open starting as either robotic, laparoscopic, or endoscopic (n=106). Wilcoxon signed-rank test was utilized for continuous variables as the data was not normally distributed. For categorical variables, Fisher's exact test was performed and Chi-squared analysis where more than two categories were evaluated. Statistical significance was set at P-value < 0.05.




Figure 1. CONSORT flow diagram illustrates the composition of the cohort.

Male Gender (%) Non-Caucasian Race (%)3170 Non-Caucasian Race (%)Hispanic Ethnicity (%)353reoperative Considerations:3008Admitted from Other Than Home (%)23Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Non-Functional Health Status (%)70Preoperative Non-Functional Health Status (%)70Preoperative Mechanical Bowel Prep (%)754Preoperative Mechanical Bowel Prep (%)70Prior Pelvic Radiotherapy (%)103SA Classification:Class 1 (%)Class 1 (%)62Class 2 (%)1792Class 3 (%)2834Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042Mu (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)233Elevated BUN (Greater than 1.6 mg/dL) (%)237Elevated BUN (Greater than 1.16 mg/dL) (%)233Elevated INR (Greater than 1.16 mg/dL) (%)237Careased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%)567Courbidities:Transfusion within 72 hours of Surgery (%)15Careat Shellitus Treated with Oral Medication (%)754	<i>862</i> (19 - 89)		
Mean Age (Range) Male Gender (%)61.28Male Gender (%)3170Non-Caucasian Race (%)353reoperative Considerations:4Admitted from Other Than Home (%)23Preoperative ASA Classification Greater than 3 (%)3008Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Voral Antibiotic Prep (%)754Preoperative Oral Antibiotic Prep (%)754Preoperative Oral Antibiotic Prep (%)75Chemotherapy (within 90 days of surgery) (%)103ISA Classification:Class 1 (%)Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)INM Classification:1499No (%)4199No (%)472M (%)61M (%)2196M1 (%)67rer-Operative Lab Values:67Elevated DVN (Greater than 1.6 mg/dL) (%)1155Elevated INR (Greater than 1.6 mg/dL) (%)233Elevated INN (Greater than 1.6 mg/dL) (%)2	(19 - 89)		n = 106
Male Gender (%) Non-Caucasian Race (%)3170 Non-Caucasian Race (%)Hispanic Ethnicity (%)353reoperative Considerations:3008Admitted from Other Than Home (%)23Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Non-Functional Health Status (%)70Preoperative Non-Functional Health Status (%)70Preoperative Mechanical Bowel Prep (%)754Preoperative Mechanical Bowel Prep (%)70Prior Pelvic Radiotherapy (%)103SA Classification:Class 1 (%)Class 1 (%)62Class 2 (%)1792Class 3 (%)2834Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042Mu (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)233Elevated BUN (Greater than 1.6 mg/dL) (%)237Elevated BUN (Greater than 1.16 mg/dL) (%)233Elevated INR (Greater than 1.16 mg/dL) (%)237Careased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%)567Courbidities:Transfusion within 72 hours of Surgery (%)15Careat Shellitus Treated with Oral Medication (%)754	(19 - 89)	to start a start	aparteria contrata
Non-Caucasian Race (%) Hispanic Ethnicity (%)1580 353reoperative Considerations:353Admitted from Other Than Home (%)23Preoperative ASA Classification Greater than 3 (%)3008Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Non-Functional Health Status (%)70Prior Peroperative Oral Antibiotic Prep (%)70Prior Pelvic Surgery (%)1608Prior Pelvic Radiotherapy (%)75Chemotherapy (within 90 days of surgery (%)103ISA Classification:Class 1 (%)Class 1 (%)62Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)MM Classification:T4 (%)T1, T1a, T3b, T3c (%)1042T4, T3, T3a, T3b, T3c (%)1042T4 (%)33Nx (%)4199N0 (%)472M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)233Elevated DIN (Greater than 1.6 mg/dL) (%)233Elevated PIT (Greater than 3.6 seconds) (%)233Elevated PIT (Greater than 3.6 seconds) (%)233Elevated INR (Greater than 1.16) (%)271Decreased Platelet Count (Less than 149 x 10°/Liter) (%)567Current Smoker (within past year) (%)155Diabetes Mellitus Treated with Oral Medication (%)78		62.58	(32 - 88)
Hispanic Ethnicity (%) reoperative Considerations: Admitted from Other Than Home (%) Preoperative ASA Classification Greater than 3 (%) Preoperative ASA Classification Greater than 3 (%) Preoperative Mon-Functional Health Status (%) 40 > 10% Decrease in Body Weight in 6 Months (%) 66 Preoperative Mechanical Bowel Prep (%) Prior Pelvic Surgery (%) 1608 Prior Pelvic Radiotherapy (%) 103 ISA Classification: Class 1 (%) Class 2 (%) 1792 Class 2 (%) 1792 Class 3 (%) 2834 Class 4 (%) 171 NM Classification: T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 344 T3, T3a, T3b, T3c (%) 1042 T4 (%) 33 Elevated INR (Greater than 1.6 mg/dL) (%) Elevated INR (Greater than 1.16) (%) 2196 M1 (%) 21	65.20%	72	67.92%
reoperative Considerations: Admitted from Other Than Home (%) Preoperative AS Classification Greater than 3 (%) Preoperative Non-Functional Health Status (%) > 10% Decrease in Body Weight in 6 Months (%) Properative Mechanical Bowel Prep (%) Preoperative Oral Antibiotic Prep (%) Prior Pelvic Surgery (%) 1608 Prior Pelvic Radiotherapy (%) ISA Classification: Class 1 (%) Class 2 (%) 1792 Class 3 (%) 2834 Class 4 (%) NM Classification: T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) NM (%) 4199 N0 (%) 2196 M1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: Elevated Creatinnie (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 1.16 mg/dL) (%) Elevated BUN (Greater than 1.16 mg/dL) (%) Elevated BUN (Greater than 1.16 mg/dL) (%) 233 Elevated INR (Greater than 1.16 (%) 233 235 236 247 247 247 247 247 257 247 257 257 257 257 257 257 257 25	32.50%	39	36.79%
Admitted from Other Than Home (%)23Preoperative ASA Classification Greater than 3 (%)3008Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Mechanical Bowel Prep (%)754Preoperative Oral Antibiotic Prep (%)750Prior Pelvic Surgery (%)1608Prior Pelvic Radiotherapy (%)75Chemotherapy (within 90 days of surgery (%)103ISA Classification:Class 1 (%)Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042MM Classification:T4 (%)T1, T1a, T1b (%)4199N0 (%)4199N0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Sclevated Dru (Greater than 1.6 mg/dL) (%)337Elevated BUN (Greater than 21 mg/dL) (%)233Elevated INR (Greater than 1.16) (%)271Decreased Platelet Count (Less than 149 x 10°/Liter) (%)567Currently on Hemodialysis (%)124Current Smoker (within past year) (%)342Diabetes Mellitus Treated with Oral Medication (%)754	7.26%	4	3.77%
Preoperative ASA Classification Greater than 3 (%)3008Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Mechanical Bowel Prep (%)754Preoperative Oral Antibiotic Prep (%)70Prior Pelvic Radiotherapy (%)103SA Classification:Class 1 (%)Class 1 (%)62Class 2 (%)1792Class 2 (%)1792Class 3 (%)2834Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042M (%)4199N0 (%)472M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Elevated DIN (Greater than 1.6 mg/dL) (%)337Elevated INR (Greater than 1.6 mg/dL) (%)233Elevated INR (Greater than 1.16) (%)231Decreased Platelet Count (Less than 149 x 10°/Liter) (%)567currently on Hemodialysis (%)124Current Smoker (within past year) (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(0.4%)	2	(1.9%)
Preoperative Non-Functional Health Status (%)40> 10% Decrease in Body Weight in 6 Months (%)66Preoperative Mechanical Bowel Prep (%)754Preoperative Oral Antibiotic Prep (%)70Prior Pelvic Surgery (%)1608Prior Pelvic Radiotherapy (%)103SA Classification:Class 1 (%)Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042NM Classification:T4 (%)33Nx (%)4199N0 (%)N0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Scheared BUN (Greater than 1.6 mg/dL) (%)233Elevated BUN (Greater than 21 mg/dL) (%)235Elevated INR (Greater than 1.16) (%)233Elevated INR (Greater than 1.16) (%)233Elevated INN (Greater than 1.16) (%)235Currently on Hemodialysis (%)124Current Smoker (within past year) (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(61.9%)	80	(75.4%)
 > 10% Decrease in Body Weight in 6 Months (%) Preoperative Mechanical Bowel Prep (%) Preoperative Oral Antibiotic Prep (%) Prior Pelvic Radiotherapy (%) Prior Pelvic Radiotherapy (%) SA Classification: Class 1 (%) Class 1 (%) Class 2 (%) I1792 Class 3 (%) 2834 Class 4 (%) T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) MC Class 1 (%) 61 M0 (%) 4199 N0 (%) 4199 N0 (%) 61 M0 (%) 2196 M1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: Elevated BUN (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 1.16) (%) 233 Elevated INR (Greater than 1.16) (%) 233 Elevated INN (Greater than 1.16) (%) 231 Elevated INN (Greater than 1.16) (%) 233 Elevated INN (Greater than 1.16) (%) 233 Elevated INN (Greater than 1.16) (%) 234 Currently on Hemodialysis (%) Currently on Hemodialysis (%) Current Smoker (within past year) (%) Diabetes Mellitus Treated with Oral Medication (%) 	(01.9%)	0	(0.0%)
Preoperative Mechanical Bowel Prep (%) Prior Pelvic Val Antibiotic Prep (%) Prior Pelvic Radiotherapy (%)754Prior Pelvic Radiotherapy (%)75Chemotherapy (within 90 days of surgery (%)103ISA Classification:Class 1 (%) Class 2 (%)62Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%) T2, T2a, T2b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042M (%)4199N0 (%)NN (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)67Elevated Creatinine (Greater than 1.6 mg/dL) (%) Elevated INR (Greater than 21 mg/dL) (%) Elevated INR (Greater than 1.6) (%)337Elevated INN (Greater than 1.6) (%) Currently on Hemodialysis (%) Diabetes Mellitus Treated with Oral Medication (%)789Diabetes Mellitus Treated with Oral Medication (%)789	(1.4%)	4	(3.8%)
Preoperative Oral Antibiotic Prep (%) Prior Pelvic Surgery (%)70Prior Pelvic Radiotherapy (%)75Chemotherapy (within 90 days of surgery) (%)103ISA Classification:Class 1 (%)62Class 2 (%)1792213Class 3 (%)28342834Class 4 (%)7111NM Classification:T1, T1a, T1b (%)3481T2, T2a, T2b (%)33433T3, T3a, T3b, T3c (%)104214T4 (%)33Nx (%)4199N0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Selevated Drateer than 1.6 mg/dL) (%)233233Elevated Dru (Greater than 21 mg/dL) (%)233218Elevated INR (Greater than 1.16) (%)233219Currently on Hemodialysis (%)124217Current Smoker (within past year) (%)567789Diabetes Mellitus Treated with Oral Medication (%)754	(15.5%)	11	(10.4%)
Prior Pelvic Surgery (%) Prior Pelvic Radiotherapy (%) 75 Chemotherapy (within 90 days of surgery) (%) 3SA Classification: Class 1 (%) Class 2 (%) 2Class 3 (%) 2834 Class 3 (%) 2834 Class 4 (%) 171 NM Classification: T1, T1a, T1b (%) T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 T4 (%) 33 Nx (%) 4199 N0 (%) 4199 N0 (%) 4199 N0 (%) 4199 N0 (%) 4199 N0 (%) 4199 N0 (%) 4199 N0 (%) 4196 M1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: Elevated Creatinine (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 2.1 mg/dL) (%) Elevated BUN (Greater than 1.16) (%) 233 Elevated PTT (Greater than 1.16) (%) 271 becreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) Diabetes Mellitus Treated with Oral Medication (%)	(1.4%)	11	(0.9%)
Prior Pelvic Radiotherapy (%) Chemotherapy (within 90 days of surgery) (%)75SA Classification:Class 1 (%) Class 2 (%)62Class 2 (%)1792Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)34T2, T2a, T2b (%)34T3, T3a, T3b, T3c (%)1042T4 (%)33Nx (%)4199N0 (%)N0 (%)2196M1 (%)61M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Elevated Creatinine (Greater than 1.6 mg/dL) (%)Elevated BUN (Greater than 21 mg/dL) (%)Elevated INR (Greater than 1.16) (%)Zereased Platelet Count (Less than 149 x 10°/Liter) (%)comorbidities:Transfusion within 72 hours of Surgery (%)Currently on Hemodialysis (%)Current Smoker (within past year) (%)Diabetes Mellitus Treated with Oral Medication (%)75	(33.1%)	41	(38.7%)
Chemotherapy (within 90 days of surgery) (%) ISA Classification: Class 1 (%) Class 2 (%) I792 Class 3 (%) Zlass 3 (%) Class 3 (%) Zlass 4 (%) I71 NM Classification: T1, T1a, T1b (%) T3, T3a, T3b, T3c (%) I042 T4 (%) 33 Nx (%) H199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) Flevated Creatinine (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 2.1 mg/dL) (%) Elevated BUN (Greater than 1.16) (%) Elevated BUN (Greater than 1.16) (%) Elevated BUN (Greater than 1.16) (%) Elevated INR (Greater than 1.16) (%) Elevated INR (Greater than 1.16) (%) 233 Elevated INR (Greater than 1.16) (%) 2196 M1 (%) T155 Elevated INR (Greater than 1.16) (%) 233 Elevated INR (Greater than 1.16) (%) 214 Currently on Hemodialysis (%) Currently on Hemodialysis (%) Diabetes Mellitus Treated with Oral Medication (%) 754	(1.5%)	41	(0.0%)
SA Classification: Class 1 (%) Class 2 (%) 7792 Class 2 (%) Class 3 (%) 2834 Class 3 (%) 2834 Class 4 (%) NM Classification: T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 NM Classification: T4 (%) 33 T3, T3a, T3b, T3c (%) 1042 NA (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: Elevated Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 21 mg/dL) (%) 337 Elevated PTT (Greater than 3.6 seconds) (%) 233 Elevated INR (Greater than 1.16) (%) 271 becreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Current Smoker (within past year) (%) 789 Diabetes Mellitus Treated with Oral Medication (%) 754	(2.1%)	3	(2.8%)
Class 1 (%) Class 2 (%)62Class 3 (%) Class 3 (%)2834Class 4 (%)171NM Classification:T1, T1a, T1b (%)T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042T4 (%)33Nx (%)4199N0 (%)472M1 (%)61M0 (%)2196M1 (%)67Elevated Creatinine (Greater than 1.6 mg/dL) (%)1155Elevated BUN (Greater than 21 mg/dL) (%)1155Elevated TT (Greater than 36 seconds) (%)233Elevated INR (Greater than 1.6) (%)271Decreased Platelet Count (Less than 149 x 10°/Liter) (%)567Currently on Hemodialysis (%)124Current Smoker (within past year) (%)789Diabetes Mellitus Treated with Oral Medication (%)754	(2.270)		(2:070)
Class 2 (%) 1792 Class 3 (%) 2834 Class 4 (%) 171 NM Classification: """"""""""""""""""""""""""""""""""""	(1.3%)	1	(0.9%)
Class 3 (%) Class 4 (%) 2834 Class 4 (%) NM Classification: 171 T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 T4 (%) 333 Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 61 Scienced Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 21 mg/dL) (%) 233 Elevated INR (Greater than 1.16) (%) 271 becreased Platelet Count (Less than 149 x 10%/Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Current Smoker (within past year) (%) 124 Current Smoker (within past year) (%) 342	(36.9%)	25	(23.6%)
Class 4 (%)171NM Classification:T1, T1a, T1b (%)3481T2, T2a, T2b (%)334T3, T3a, T3b, T3c (%)1042T4 (%)33Nx (%)4199N0 (%)472N1 (%)611M0 (%)2196M1 (%)61M0 (%)2196M1 (%)61Stevated Creatinine (Greater than 1.6 mg/dL) (%)1155Elevated BUN (Greater than 21 mg/dL) (%)233Elevated PTT (Greater than 36 seconds) (%)233Elevated INR (Greater than 1.6) (%)271Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%)567Currently on Hemodialysis (%)124Current Smoker (within past year) (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(58.3%)	71	(67.0%)
NM Classification: T1, T1a, T1b (%) 3481 T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 T4 (%) 33 Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: 67 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 36 seconds) (%) 233 Elevated ITR (Greater than 1.6 mg/dL) (%) 2567 comorbidities: 567 Comorbidities: 7 Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(3.5%)	8	(7.5%)
T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 T4 (%) 33 Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 ree-Operative Lab Values: 67 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 1155 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 1.6) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 789 Diabetes Mellitus Treated with Oral Medication (%) 754	()	_	(
T2, T2a, T2b (%) 334 T3, T3a, T3b, T3c (%) 1042 T4 (%) 33 Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 ree-Operative Lab Values: 67 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 1155 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 1.6) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 789 Diabetes Mellitus Treated with Oral Medication (%) 754	(71.6%)	57	(53.8%)
T3, T3a, T3b, T3c (%) 1042 T4 (%) T4 (%) Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: 1155 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 26 seconds) (%) 233 Elevated PTT (Greater than 1.6) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Current Smoker (within past year) (%) 789 789 Diabetes Mellitus Treated with Oral Medication (%) 754	(6.9%)	8	(7.5%)
Nx (%) 4199 N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: 67 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 21 mg/dL) (%) 233 Elevated INR (Greater than 1.16) (%) 271 becreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(21.4%)	32	(30.2%)
N0 (%) 472 N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: 337 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 1155 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 1.60 (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 382 Diabetes Mellitus Treated with Oral Medication (%) 754	(0.7%)	9	(8.5%)
N1 (%) 61 M0 (%) 2196 M1 (%) 67 re-Operative Lab Values: 337 Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated TI (Greater than 36 seconds) (%) 233 Elevated INR (Greater than 1.16) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 Comorbidities: Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(86.4%)	74	(69.8%)
M0 (%) M1 (%) M1 (%) Elevated Creatinine (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 21 mg/dL) (%) Elevated BUN (Greater than 21 mg/dL) (%) Elevated PTT (Greater than 21 mg/dL) (%) Elevated INR (Greater than 1.16) (%) Elevated INR (Greater than 1.16) (%) Elevated INR (Greater than 1.16) (%) Transfusion within 72 hours of Surgery (%) Currently on Hemodialysis (%) Currently on Hemodialysis (%) Diabetes Mellitus Treated with Oral Medication (%) Tsa	(9.7%)	21	(19.8%)
M1 (%) re-Operative Lab Values: Elevated Creatinine (Greater than 1.6 mg/dL) (%) Elevated BUN (Greater than 21 mg/dL) (%) Elevated PTT (Greater than 36 seconds) (%) Elevated INR (Greater than 1.16) (%) Cereased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) comorbidities: Transfusion within 72 hours of Surgery (%) Currently on Hemodialysis (%) Current Smoker (within past year) (%) Diabetes Mellitus Treated with Oral Medication (%) 754	(1.3%)	4	(3.8%)
re-Operative Lab Values: Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 36 seconds) (%) 233 Elevated INR (Greater than 1.66 (%) 271 Decreased Platelet Count (Less than 149 x 10°/Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 342 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(45.2%)	44	(41.5%)
Elevated Creatinine (Greater than 1.6 mg/dL) (%) 337 Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 36 seconds) (%) 233 Elevated INR (Greater than 1.16) (%) 271 becreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(1.4%)	5	(4.7%)
Elevated BUN (Greater than 21 mg/dL) (%) 1155 Elevated PTT (Greater than 36 seconds) (%) 233 Elevated INR (Greater than 1.16) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754			
Elevated PTT (Greater than 36 seconds) (%) 233 Elevated INR (Greater than 1.16) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 iomorbidities: 567 Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(6.9%)	15	(14.2%)
Elevated INR (Greater than 1.15) (%) 271 Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) 567 comorbidities: 567 Transfusion within 72 hours of Surgery (%) 15 Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 789 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754	(23.8%)	33	(31.1%)
Decreased Platelet Count (Less than 149 x 10 ⁹ /Liter) (%) comorbidities: Transfusion within 72 hours of Surgery (%) Currently on Hemodialysis (%) Current Smoker (within past year) (%) Diabetes Mellitus Treated with Insulin (%) Diabetes Mellitus Treated with Oral Medication (%)	(4.8%)	13	(12.3%)
Comorbidities: Transfusion within 72 hours of Surgery (%) Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) Diabetes Mellitus Treated with Insulin (%) Diabetes Mellitus Treated with Oral Medication (%) 754	(5.6%)	12	(11.3%)
Transfusion within 72 hours of Surgery (%)15Currently on Hemodialysis (%)124Current Smoker (within past year) (%)789Diabetes Mellitus Treated with Insulin (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(11.7%)	17	(16.0%)
Currently on Hemodialysis (%) 124 Current Smoker (within past year) (%) 789 Diabetes Mellitus Treated with Insulin (%) 342 Diabetes Mellitus Treated with Oral Medication (%) 754			10716 - 10870 20120 - 1
Current Smoker (within past year) (%)789Diabetes Mellitus Treated with Insulin (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(0.3%)	2	(1.9%)
Diabetes Mellitus Treated with Insulin (%)342Diabetes Mellitus Treated with Oral Medication (%)754	(2.6%)	8	(7.5%)
Diabetes Mellitus Treated with Oral Medication (%) 754	(16.2%)	13	(12.3%)
	(7.0%)	8	(7.5%)
	(15.5%)	18	(17%)
	(3.2%)	10	(9.4%)
	(3.8%)	2	(1.9%)
	(61.4%)	69	(65.1%)
	(4.0%)	5	(4.7%)
	(5.9%) (2.6%)	12 6	(11.3%) (5.7%)

Table 2. Postoperative Outcomes Frequency Table, Unplanned conversion to open

nts T-test for continuous variables or Chi-Square for categorical variable NSA = American Society of Anesthesiologists, COPD = Chronic Obstructive Pulmonary Disorder, BUN: Blood

	Total	Cohort	Unplanned (Conversion to Open	Minimally I	nvasive Surgery	P Valu
	n = 4	4862	1	n = 106	n :	= 4756	
Dutcome Variables							
Readmission to Hospital (%)	227	(4.7%)	17	(16.0%)	210	(4.4%)	P < 0.0
Pt Requiring Bleeding Transfusion (%)	189	(3.9%)	35	(33.0%)	154	(3.2%)	P < 0.0
Mean Total Operating Time in Minutes (Range)	176.4	(4 - 769)	255.08	(66 - 732)	174.7	(4 - 769)	P < 0.0
Mean Length of Hospital Stay (Range)	2.4	(0 - 36)	5.07	(1 - 27)	2.3	(0 - 36)	P < 0.0
Mean Days from Operation to Discharge (Range)	2.1	(0 - 30)	0.85	(0 - 21)	2.2	(0 - 30)	P < 0.0
Superficial Incisional Surgical Site Infection (%)	62	(1.3%)	3	(2.8%)	59	(1.2%)	
Deep Incisional Surgical Site Infection (%)	7	(0.1%)	2	(1.9%)	5	(0.1%)	P < 0.0
Organ Space Incisional Surgical Site Infection (%)	27	(0.6%)	6	(5.7%)	21	(0.4%)	P < 0.0
Sepsis (%)	20	(0.4%)	2	(1.9%)	18	(0.4%)	P = 0.0
Septic Shock (%)	10	(0.2%)	1	(0.9%)	9	(0.2%)	
Urinary Tract Infection (%)	52	(1.1%)	0	(0.0%)	52	(1.1%)	
Acute Renal Failure (%)	15	(0.3%)	4	(3.8%)	11	(0.2%)	P < 0.0
Pneumonia (%)	54	(1.1%)	1	(0.9%)	53	(1.1%)	
CVA/Stroke with Neurological Deficit (%)	6	(0.1%)	0	(0.0%)	6	(0.1%)	
Cardiac Arrest Requiring CPR (%)	16	(0.3%)	1	(0.9%)	15	(0.3%)	
Myocardial Infarction (%)	26	(0.5%)	1	(0.9%)	25	(0.5%)	
Pulmonary Embolism (%)	24	(0.5%)	3	(2.8%)	21	(0.4%)	P < 0.0
DVT/Thrombophlebitis (%)	26	(0.5%)	4	(3.8%)	22	(0.5%)	P < 0.0
Discharge to SNF (%)	119	(2.5%)	11	(10.4%)	108	(2.3%)	
Discharge to Home (%)	4743	(97.6%)	95	(89.6%)	4648	(97.7%)	
Rectal Injury (%)	3	(0.1%)	0	(0.0%)	3	(0.1%)	
Unplanned Intubation (%)	18	(0.4%)	0	(0.0%)	18	(0.4%)	
Wound Disruption (%)	17	(0.4%)	4	(3.8%)	13	(0.3%)	P < 0.0
On Ventilator Greater than 48 Hours (%)	17	(0.3%)	2	(1.95)	15	(0.3%)	P < 0.0
Clostridium Difficile Colitis (%)	10	(0.2%)	1	(0.9%)	9	(0.2%)	
Prolonged NPO or NGT Use (%)	82	(1.7%)	13	(12.3%))	69	(1.5%)	P < 0.0
Lymphocele/Lymphatic Leak (%)	82	(1.7%)	6	(5.7%)	76	(1.6%)	P < 0.0
Unplanned Reoperation (%)	85	(1.7%)	10	(10.9%)	75	(1.6%)	P < 0.0

P Value represents T-Test for continuous variables and Chi-Square for categorical variables.

UTI = Urinary Tract Infection, PNA = Pneumonia, DVT = Deep Vein Thrombosis, SNF = Skilled Nursing Facility, NPO = Nothing by mouth, NGT = Nasoaastric Tube

hrectomy							
Minimally II n =	P Value						
	1700						
61.25	(19 - 89)						
3098	65.14%						
1541	32.40%						
349	7.34%						
21	(0.4%)						
2928	(61.6%)	P < 0.01					
40	(0.8%)						
62	(1.3%)	P = 0.02					
743	(15.6%)						
69	(1.5%)						
1567	(32.9%)						
75	(1.6%)						
100	(2.1%)						
61	(1.3%)						
1767	(37.2%)	P < 0.01					
2763	(58.1%)						
163	(0.04%)	P = 0.02					
3424	(72.0%)	P < 0.01					
298	(6.3%)						
1010	(21.2%)	P = 0.03					
24	(0.2%)	P < 0.01					
4125	(86.7%)	P < 0.01					
451	(9.5%)	P < 0.01					
57	(1.2%)	P = 0.02					
2152	(45.2%)						
62	(1.3%)	P < 0.01					
322	(6.8%)	P < 0.01					
1122	(23.6%)						
220	(4.6%)	P < 0.01					
259	(5.5%)	P < 0.01					
550	(11.6%)						
13	(0.3%)	P < 0.01					
116	(2.4%)	P < 0.01					
776	(16.3%)						
334	(7.0%)						
736	(15.5%)						
145	(3.0%)	P < 0.01					
182	(3.8%)						
2915	(61.3%)						
190	(4.0%)						
273	(5.8%)	P = 0.03					
118	(2.55)	P = 0.04					

Results

The unplanned conversion to open rate was 2.2%. The age (mean (SD)) of the cohort was 62.6 (11.2) and 61.3 (12.2) for the unplanned and the planned group. There was a baseline difference with preoperative labs including BUN, creatinine, PTT, and INR. An increased incidence of T3 and T4 (30.2% and 8.5%) in the unplanned group compared to the (21.2% and 0.50%) in the planned group was noted. ASA classification 4 also favored the unplanned group vs. planned group (Table 1). The outcome variables were also compared between the unplanned and the planned group (Table 2).

Discussion

Based on our study, multiple factors were associated with conversion to open in nephrectomy. Higher tumor stage, ASA classification, kidney function, and PT/INR were all predictive factors of conversion to open in nephrectomies. The open group had worse clinical outcomes including length of hospital stay, discharge to nursing care, prolonged NPO/NGT, and lymph leak.

Limitations

This study was performed retrospectively and, therefore, no causality can be drawn from these findings. Another limitation is surgeon preference when converting to open nephrectomy. In these cases, each urological surgeon may have a different threshold for open conversion, and this variable cannot be controlled for. Although we performed a multivariable statistical regression, unaccounted for confounding variables, other than primary surgeon, could potentially influence the data.

References

- Miller DC, Saigal CS, Banerjee M, Hanley J, Litwin MS, Urologic Diseases in America Project. Diffusion of 1. surgical innovation among patients with kidney cancer. Cancer 2008;112:1708-1717.
- 2. Gill IS, Sung GT, Hsu TH, Meraney AM. Robotic remote laparoscopic nephrectomy and adrenalectomy: The initial experience. J Urol 2000;164:2082-2085.
- Golombos DM, Chughtai B, Trinh QD, Thomas D, Mao J, Te A, O'Malley P, Scherr DS, Del Pizzo J, Hu JC, 3. Sedrakyan A. Minimally invasive vs open nephrectomy in the modern era: does approach matter? World J Urol. 2017 Oct;35(10):1557-1568. doi: 10.1007/s00345-017-2040-6. Epub 2017 May 5. PMID: 28477204
- Khanna A, Campbell SC, Murthy PB, Ericson KJ, Nyame YA, Abouassaly R. Unplanned Conversion from 4. Minimally Invasive to Open Kidney Surgery: The Impact of Robotics. J Endourol. 2020 Sep;34(9):955-963. doi: 10.1089/end.2020.0357. Epub 2020 Aug 6. PMID: 32597204..
- Razdan S, Okhawere K, Wilson M, Nkemdirim W, Korn T, Meilika K, Badani K. Conversion to Open Radical or Partial Nephrectomy Associated with Unplanned Hospital Readmission After Attempted Minimally Invasive Approach. J Laparoendosc Adv Surg Tech A. 2021 Dec 28. doi: 10.1089/lap.2021.0537. Epub ahead of print. PMID: 34962141.